INSIGHT-Paying for gene therapy: are annuities the next big thing?
February 19, 2015 at 01:00 AM EST
LOS ANGELES, Feb 19 (Reuters) - As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines.